SCHEMBL14711343

SCHEMBL14711343

Cc1snc(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)c1NC(=O)OC(C)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 17/20 0.64
LPAR3 Q9UBY5 8/20 0.62
LPAR2 Q9HBW0 2/20 0.52
ABCC4 O15439 2/20 0.43
ABCC3 O15438 1/20 0.43
ABCB11 O95342 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2C9 P11712 1/20 0.43
ABCB4 P21439 1/20 0.43
ABCC2 Q92887 1/20 0.43
SLCO1B3 Q9NPD5 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
PTGS1 P23219 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14710223 0.89 LPAR1 (0.68) LPAR1LPAR3LPAR2
SCHEMBL14711353 0.89 LPAR1 (0.68) LPAR1LPAR3LPAR2
SCHEMBL14790358 0.83 LPAR1 (0.54) LPAR1LPAR3ABCC4ABCC3ABCB11
SCHEMBL11895960 0.82 LPAR1 (0.72) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL9939480 0.82 LPAR1 (0.72) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL14711823 0.82 LPAR1 (0.64) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL14711113 0.82 LPAR1 (0.64) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL14711706 0.82 LPAR1 (0.66) LPAR1LPAR3ABCC4ABCC3ABCB11
SCHEMBL14711563 0.82 LPAR1 (0.66) LPAR1LPAR3ABCC4ABCC3ABCB11
SCHEMBL14710431 0.81 LPAR1 (0.66) LPAR1LPAR3LPAR2ABCC4ABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.